MedTrace Logo

Efficacy of Pilsicainide After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation

NCT01775891 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 245

Last updated 2013-02-26

No results posted yet for this study

Summary

Investigators hypothesized that the use of Pilsicainide after radiofrequency ablation of AF could reduce the incidence of recurrence of atrial arrhythmia during follow up compared with other class IC antiarrhythmic drugs.

Conditions

  • Paroxysmal Atrial Fibrillation

Interventions

DRUG

pilsicainide

The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.

DRUG

other class IC antiarrhythmic drug

Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.

Sponsors & Collaborators

  • Korea University

    lead OTHER

Principal Investigators

  • Young-Hoon Kim, MD., PhD · Arrhythmia center, Anam hospital, Korea university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01775891 on ClinicalTrials.gov